Cornileus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.59 Cr
as on 16-11-2024
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 48.71 Cr
as on 16-11-2024
- Satisfied Charges ₹ 34.85 Cr
as on 16-11-2024
- Revenue 14.70%
(FY 2023)
- Profit -4.54%
(FY 2023)
- Ebitda 19.14%
(FY 2023)
- Net Worth 29.56%
(FY 2023)
- Total Assets 27.55%
(FY 2023)
About Cornileus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.59 Cr.
The company currently has active open charges totaling ₹48.71 Cr. The company has closed loans amounting to ₹34.85 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kiran Nalamothu, Vijayalakshmi Nalamothu, Venkat Jagarlamudi, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239TG2001PTC038288
- Company No.
038288
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2001
- Date of AGM
25 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cornileus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Nalamothu  | Managing Director | 28-Dec-2001 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijayalakshmi Nalamothu | Director | 17-Oct-2017 | Current |
| Venkat Jagarlamudi | Director | 28-Dec-2020 | Current |
| Jagarlamudi Babu | Director | 28-Dec-2020 | Current |
Financial Performance of Cornileus Pharmaceuticals.
Cornileus Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.7% increase. The company also saw a slight decrease in profitability, with a 4.54% decrease in profit. The company's net worth Soared by an impressive increase of 29.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cornileus Pharmaceuticals?
In 2022, Cornileus Pharmaceuticals had a promoter holding of 39.31% and a public holding of 60.69%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jayansree Pharma Private LimitedActive 10 years 9 monthsKiran Nalamothu and Jagarlamudi Babu are mutual person
- Regius Pharma Private LimitedActive 4 years 1 month
Kiran Nalamothu and Vijayalakshmi Nalamothu are mutual person
- Ananda Profiles Private LimitedActive 25 years 24 days
Venkat Jagarlamudi and Jagarlamudi Babu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 May 2024 | ₹7.50 Cr | Open |
State Bank Of India Creation Date: 07 Feb 2020 | ₹31.71 Cr | Open |
Others Creation Date: 01 Feb 2019 | ₹9.50 Cr | Open |
How Many Employees Work at Cornileus Pharmaceuticals?
Cornileus Pharmaceuticals has a workforce of 124 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cornileus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cornileus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
